Skip to main content
SpringerLink
Log in

Pharmacogenetics in the Brazilian Population

  • Chapter
Racial Identities, Genetic Ancestry, and Health in South America

Abstract

“Pharmacogenetics deals with pharmacological responses and their mod-ification by hereditary influences.” 1 This definition, offered by Werner Kalow in the first book dedicated to pharmacogenetics (Kalow, 1962), highlights the three pillars of this discipline: pharmacology, genetics, and human diversity. Pharmacogenetics has evolved greatly over the 50 years elapsed since Kalow’s book was published and was rechristened as phar- macogenomics in the fashion of the “omics” revolution, but its conceptual development and praxis remain contingent upon a better understanding of human genomic diversity and its impact on drug pharmacokinetics and pharmacodynamics. In this chapter, I present an overview of phar- macogenetic/pharmacogenomic (PGx) studies in Brazilians, starting with a brief review of the heterogeneity and structure of the Brazilian population, which have important implications for the conceptual development and clinical implementation of PGx in this country.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Bastos-Rodrigues, L. et al. (2006) The genetic structure of human populations studied through short insertion-deletion polymorphisms. Annals of Human Genetics, 70, pp. 658–665.

    Article  Google Scholar 

  • Estrela, R. C. E. et al. (2008a) The distribution of ABCB1 polymorphisms among Brazilians: Impact of population admixture. Pharmacogenomics, 9, pp. 267–276.

    Article  Google Scholar 

  • Estrela, R. C. E. et al. (2008b) CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clinical Pharmacology&Therapeutics, 84, pp. 205–207.

    Google Scholar 

  • Estrela, R. C. E. et al. (2009) ABCB1 polymorphisms have no impact on the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV- i nfected men under stable antiretroviral therapy. Pharmacogenomics, 10, pp. 311–318.

    Article  Google Scholar 

  • Gage, B. F. et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology&Therapeutics, 84, pp. 326–331.

    Google Scholar 

  • Hartkoorn, R. C. et al. (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics, 20, pp. 112–120.

    Google Scholar 

  • Hutz, M. H., and Fiegenbaum, M. (2008) Impact of genetic polymorphisms on the efficacy of HMG-CoA reductase inhibitors. American Journal of Cardiovascular Drugs, 8, pp. 161–170.

    Article  Google Scholar 

  • Jaja, C. et al. (2008) Cytochrome p450 enzyme polymorphism frequency in indigenous and native American populations, a systematic review. Community Genetics, 11, pp. 141–149.

    Article  Google Scholar 

  • Josephson, F. et al. (2007) CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clinical Pharmacology&Therapeutics, 81, pp. 708–712.

    Google Scholar 

  • Kalow, W. (1962) Pharmacogenetics, Heredity and the Response to Drugs. Philadelphia: WB Saunders Co.

    Google Scholar 

  • Kieling, C. et al. (2010) A current update on ADHD pharmacogenomics. Pharmacogenomics, 11, pp. 407–419.

    Article  Google Scholar 

  • Kohlrausch, F. B. et al. (2010) The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. British Journal of Clinical Pharmacology, 69, pp. 95–98.

    Article  Google Scholar 

  • Kohlrausch, F. B. et al. (2008) G-protein gene 825C > T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics, 9, pp. 1429–1436.

    Article  Google Scholar 

  • McDonald, M. G. et al. (2009) CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Molecular Pharmacology, 75, pp. 1337–1346.

    Article  Google Scholar 

  • Nagassaki, S. et al. (2009) eNOS T-786C polymorphism affects atorvastatin- i nduced changes in erythrocyte membrane fluidity. European Journal of Clinical Pharmacology, 65, pp. 385–392.

    Article  Google Scholar 

  • Parra, F. C. et al. (2003) Color and genomic ancestry in Brazilians. Proceedings of the National Academy of Sciences of the United States of America, 100, pp. 177–182.

    Article  Google Scholar 

  • Pena, S. D. J. et al. (2009) DNA tests probe the genomic ancestry of Brazilians. Brazilian Journal of Medical and Biological Research, 42, pp. 870–876.

    Article  Google Scholar 

  • Perini, J. A. et al. (2008a) Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients. Clinical Pharmacology&Therapeutics, 84, pp. 722–728.

    Google Scholar 

  • Perini, J. A. et al. (2008b) VKORC1 polymorphisms in Amerindian populations of Brazil. Pharmacogenomics, 9, pp. 1623–1629.

    Article  Google Scholar 

  • Perini, J. A. et al. (2010) Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clinical Pharmacology&Therapeutics, 87, pp. 417–420.

    Google Scholar 

  • Perini, J. A., and Suarez-Kurtz, G. (2006) Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam. Clinical Pharmacology&Therapeutics, 80, pp. 549–551.

    Google Scholar 

  • Perini, J. A. et al. (2009) Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Brazilian Journal of Medical and Biological Research, 42, pp. 1179–1184.

    Article  Google Scholar 

  • Perini, J. A. et al. (2005) Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clinical Pharmacology&Therapeutics, 78, pp. 362–369.

    Google Scholar 

  • Pritchard, J. K. et al. (2000) Inference of population structure using multilocus genotype data. Genetics, 155, 945–959.

    Google Scholar 

  • Rebecchi, I. M. et al. (2009) ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochemical Pharmacology, 77, pp. 66–75.

    Article  Google Scholar 

  • Ribeiro, D. (1995) O povo brasileiro: A formação e o sentido do Brasil. São Paulo: Companhia das Letras.

    Google Scholar 

  • Rodrigues, A. C. et al. (2007) The genetic determinants of atorvastatin response. Current Opinion in Molecular Therapeutics, 9, pp. 545–553.

    Google Scholar 

  • Salzano, F. M., and Bortolini, M. C. (2002) The Evolution and Genetics of Latin American Populations. Cambridge: Cambridge University Press.

    Google Scholar 

  • Sandrim, V. C. et al. (2010) eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics Journal, 10, pp. 40–45.

    Article  Google Scholar 

  • Suarez-Kurtz, G. (2004) Pharmacogenomics in admixed populations: The Brazilian pharmacogenetics/pharmacogenomics network—REFARGEN. Pharmacogenomics Journal, 4, pp. 347–438.

    Article  Google Scholar 

  • Suarez-Kurtz, G. (2005) Pharmacogenetics in admixed populations. Trends in Pharmacological Sciences, 26, pp. 196–201.

    Article  Google Scholar 

  • Suarez-Kurtz, G. (2008a) The implications of population admixture in race- based therapy. Clinical Pharmacology&Therapeutics, 83, pp. 399–400.

    Google Scholar 

  • Suarez-Kurtz, G. (2008b) Ethnic differences in drug therapy, a pharmacogenom- ics perspective. Expert Review in Clinical Pharmacology, 1, pp. 337–339.

    Article  Google Scholar 

  • Suarez-Kurtz, G. (2010) Pharmacogenetics in the Brazilian population. Frontiers in Pharmacology, 1, pp. 1–18.

    Article  Google Scholar 

  • Suarez-Kurtz, G. et al. (2010a) VKORC1 polymorphisms in Brazilians, comparison with the Portuguese and Portuguese-speaking Africans and pharmaco- genetic implications. Pharmacogenomics, 11, pp. 1257–1267.

    Article  Google Scholar 

  • Suarez-Kurtz, G. et al. (2010b) Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J, Dec 21 epub ahead of print.

    Google Scholar 

  • Suarez-Kurtz, G. and Pena, S. D. J. (2007) Pharmacogenetic studies in the Brazilian population. In: Suarez-Kurtz, G. (ed.) Pharmacogenomics in Admixed Populations. Austin: Landes, pp. 75–98.

    Google Scholar 

  • Suarez-Kurtz, G. et al. (2007a) Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenetics and Genomics, 17, pp. 765–771.

    Article  Google Scholar 

  • Suarez-Kurtz, G. et al. (2007b) Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics, 8, pp. 1299–1306.

    Article  Google Scholar 

  • Suarez-Kurtz, G. et al. (2009) Relative contribution of VKORC1, CYP2C9 and INR response to warfarin stable dose. Blood, 113, pp. 4125–4126.

    Article  Google Scholar 

  • Vargens, D. D. et al. (2008) Distribution of the GNB3 825C > T polymorphism among Brazilians, impact of population structure. European Journal of Clinical Pharmacology, 3, pp. 253–256.

    Article  Google Scholar 

  • Vianna-Jorge, R. et al. (2004) CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clinical Pharmacology&Therapeutics, 76, pp. 18–26.

    Google Scholar 

Download references

Authors
  1. Guilherme Suarez-Kurtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Sahra Gibbon Ricardo Ventura Santos Mónica Sans

Copyright information

© 2011 Sahra Gibbon, Ricardo Ventura Santos, and Mónica Sans

About this chapter

Cite this chapter

Suarez-Kurtz, G. (2011). Pharmacogenetics in the Brazilian Population. In: Gibbon, S., Santos, R.V., Sans, M. (eds) Racial Identities, Genetic Ancestry, and Health in South America. Palgrave Macmillan, New York. https://doi.org/10.1057/9781137001702_6

Download citation

Publish with us

Policies and ethics

Search

Navigation